Latest Materials News

Medallion Metals has significantly expanded its sulphide Mineral Resource Estimate at the Ravensthorpe Gold Project to 950,000 ounces gold equivalent, underpinning a rapid move toward production with a feasibility study due in October and a Final Investment Decision expected by year-end.

Hartshead Resources has voluntarily suspended trading on the ASX pending a significant announcement about a well carry agreement linked to its P2607 Licence. The suspension is set to last until the announcement or early September.

EQ Resources has successfully commissioned a third XRT ore sorter at its Saloro tungsten operation, increasing sorting capacity by 50% and improving processing efficiency. An updated ore reserve estimate is expected in early Q4 2025, reflecting operational gains and stronger tungsten prices.

Greatland Resources Limited has reported a robust unaudited FY2025 result, generating $337.3 million net profit after tax from seven months of Telfer gold-copper mine operations, alongside a successful ASX listing and strong cash flow.

Invion Limited has affirmed its compliance with ASX disclosure rules following the US FDA’s granting of Orphan Drug Designation for its anal cancer treatment candidate INV043. The company detailed the timing and verification process behind its announcement.

Zoono Group Limited reported a 19.1% revenue increase to NZ$1.25 million for FY2025, alongside a significantly reduced net loss. The company is pivoting towards B2B markets, focusing on antimicrobial and shelf-life extension technologies, supported by a recent AUD 1.78 million capital raise.

Lynas Rare Earths reported FY25 results featuring record NdPr output and the first commercial heavy rare earths production outside China, alongside a $750 million equity raise to fund its ambitious Towards 2030 growth strategy.

Lynas Rare Earths reports FY25 revenue growth amid profit decline, completes major capital projects, and launches a $750 million equity raise to fund its expansive Towards 2030 strategy.

Lynas Rare Earths reported a 20% revenue increase in FY25 driven by higher NdPr sales, yet net profit fell sharply amid ramp-up costs and market challenges. The company completed key growth projects and unveiled its Towards 2030 strategy focused on downstream expansion.

Emyria Limited reports a reduced net loss of $3.14 million for FY2025, driven by strategic expansion in psychedelic-assisted mental health treatments and key partnerships including insurer Medibank. The company advances clinical services while continuing R&D on proprietary medicines.

Comms Group Limited reported a 2.1% revenue increase to $56.6 million for FY25, driven by organic growth and the strategic acquisition of TasmaNet. Despite this, underlying EBITDA declined 13.6%, reflecting investments and one-off revenue adjustments.

Lumos Diagnostics reported an 11.4% revenue increase to US$12.4 million for FY2025, yet still posted a significant net loss amid auditor concerns over its future viability.